MAP2K7 and acute myeloid leukemia: An additional effect of LSD1 inhibition with GSK2879552 is the hypersensitization it causes to MEK inhibitors in AML cells, in which the activation of the MEK pathway is a mechanism of resistance to LSD1 inhibitors [71].